anti-EGFR mAbs (ICR)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-EGFR mAbs (ICR)
Drug Alias Namemonoclonal antibodies c-erbB (ICR)monoclonal antibodies (ICR)MAb ICR-62
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesInstitute Of Cancer Research
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesInstitute Of Cancer Research
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A